Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prophylactic Treatment With Recombinant Factor VIIa (rFVIIa, NovoSeven®) in Haemophilia Patients With Inhibitors

NCT00882778 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00882778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00882778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prophylactic Treatment With Recombinant Factor VIIa (rFVIIa, NovoSeven®) in Haemophilia Patients With Inhibitors
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
April 30, 2009
Completion date
May 31, 2010
Enrollment
86 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a with inhibitors, haemophilia b with inhibitors